Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Adicet Bio Inc ACET

Healthcare Biotechnology
Adicet Bio, Inc. is a clinical stage biotechnology company. The Company is engaged in advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the... see more

Recent & Breaking News (NDAQ:ACET)

resTORbio, Inc. Announces Closing Public Offering of Common Stock

GlobeNewswire March 22, 2019

resTORbio, Inc. Announces Pricing of Public Offering of Common Stock

GlobeNewswire March 19, 2019

resTORbio, Inc. Announces Proposed Public Offering of Common Stock

GlobeNewswire March 18, 2019

resTORbio Reports Fourth Quarter and Full Year 2018 Financial Results

GlobeNewswire March 18, 2019

resTORbio Announces Positive End-of-Phase 2 Meeting with FDA and Planned Initiation of Global Phase 3 Program for RTB101

GlobeNewswire March 18, 2019

resTORbio to Present at 8th Annual SVB Leerink Global Healthcare Conference

GlobeNewswire February 21, 2019

resTORbio Appoints Erkan Baloglu, Ph.D., M.B.A., as Vice President of Drug Discovery and Medicinal Chemistry

GlobeNewswire February 6, 2019

resTORbio to Host Key Opinion Leader Symposium on TORC1 Inhibition and Neurodegenerative Disease

GlobeNewswire January 31, 2019

resTORbio Appoints William Marshall, M.D., as Vice President of Medical Sciences

GlobeNewswire December 19, 2018

resTORbio Reports Third Quarter 2018 Financial Results

GlobeNewswire November 13, 2018

resTORbio Co-Founder and Chief Medical Officer Joan Mannick, M.D., to Present on TORC1 Inhibition at The Gerontological Society of America 2018 Annual Scientific Meeting

GlobeNewswire November 8, 2018

resTORbio to Present at Upcoming Investor Conferences in November

GlobeNewswire November 7, 2018

resTORbio Appoints Michael Grissinger to its Board of Directors

GlobeNewswire November 6, 2018

resTORbio Announces Additional RTB101 Phase 2b Data Demonstrating Decreased Incidence of Laboratory-Confirmed RTIs with Severe Symptoms, Total Infections and UTIs

GlobeNewswire October 16, 2018

resTORbio to Present at 2018 Cantor Fitzgerald Global Healthcare Conference

GlobeNewswire September 24, 2018

resTORbio Appoints Meredith Manning as Chief Commercial Officer

GlobeNewswire September 18, 2018

resTORbio to Present at Wells Fargo 2018 Healthcare Conference

GlobeNewswire August 29, 2018

resTORbio Appoints Jeffrey Chodakewitz, M.D., to its Board of Directors

GlobeNewswire August 15, 2018

resTORbio Reports Second Quarter 2018 Financial Results

GlobeNewswire August 9, 2018

resTORbio to Present at the Canaccord Genuity 38th Annual Growth Conference

GlobeNewswire July 30, 2018